Interviews with Key Opinion Leaders (KOLs) from Across the Stem Cell Industry

BioInformant's Founder, Cade Hildreth, has interviewed hundreds of key opinion leaders (KOL's) from across the stem cell industry.

Educating Physicians about Regenerative Medicine with Boston Biolife

April 20, 2016 By Cade Hildreth (CEO) Leave a Comment

I am honored to release this interview with Joseph Krieger, President of Boston Biolife. Boston BioLife is an innovative organization that presents workshops for physicians and scientists to educate them about novel advances in regenerative medicine. Its training programs are characterized by using both didactic and interactive, “hands-on” approaches, which physicians can get ACCME accreditation for attending. Boston Biolife’s next event will be “Hands–On Stem Cell Therapies and Biologics for the Clinical Application of Pain Management” in Boston, MA, on July 16-17, 2016.

To learn more, enjoy the full interview with Joseph Krieger below. [Read more…]

Will Universal Cell’s Gene-Editing Tech Create Universally Compatible Stem Cells?

March 10, 2016 By Cade Hildreth (CEO) Leave a Comment

Universal Cells Inc. is a private biotechnology company based in Seattle, Washington that is enabling the field of regenerative medicine by creating stem cells that are universally compatible. Its technology is based on intellectual property (IP) in-licensed from the University of Washington and includes methods for genome editing in human stem cells via homologous recombination with recombinant adeno-associated virus (rAAV) vectors, as well as specific HLA-engineering strategies.

I had the honor to interview Gregory Block, VP of Business Development for Universal Cells. Universal Cells is a private biotechnology company based in Seattle, Washington, that is revolutionizing the stem cell field by creating stem cells that are universally compatible.

[Note: Universal Cells was acquired by Japanese biopharmaceutical giant Astellas Pharma on February 14, 2018, for $102.5 million plus potential milestones.]*
[Read more…]

Interview with Dr. Jon Rowley, CEO of RoosterBio – Radically Changing the Use of Stem Cells

March 3, 2016 By Cade Hildreth (CEO) Leave a Comment

RoosterBio

This article is an interview with the Founder and Chief Executive Officer (CEO) of RoosterBio, Dr. Jon Rowley. RoosterBio is an innovative company that provides standardized stem cell product platforms to enable rapid clinical and commercial translation.

Specifically, RoosterBio’s products are high volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems.

In this interview, we explore how RoosterBio is “radically changing the use of stem cells.” Enjoy! [Read more…]

Interview with Dr. Racheli Ofir, VP of Research & Intellectual Property at Pluristem Therapeutics

February 22, 2016 By Cade Hildreth (CEO) 1 Comment

I had the honor of interviewing Dr. Racheli Ofir, Vice President (VP) of Research & Intellectual Property at Pluristem Therapeutics. Pluristem is a clinical-stage biotechnology company that uses placental cells and a proprietary, three-dimensional technology platform to develop cell therapies for a broad range of diseases.

The company is at the forefront of placental-based cell therapy applications. In addition to other accomplishments, the company is now preparing for a proposed Phase III trial of its PLX-PAD cells in the treatment of critical limb ischemia (CLI).

Interview with Dr. Racheli Ofir, VP of Research & IP at Pluristem Therapeutics

Racheli Ofir, VP Research & Intellectual Property at Pluristem Therapeutics — Dr. Racheli Ofir

Cade Hildreth: What is your background and how did you get involved with Pluristem?

Dr. Racheli Ofir: I did my PhD and post-doc in cellular and developmental biology at the Technion in Haifa. I joined Pluristem 9 years ago and am responsible for the research activity of the company including efficacy and safety studies of Pluristem placenta-derived cells, as well as revealing the underlying mechanism of action of the cells. [Read more…]

Preparations Begin for Phase II Stem Cell Trial for Multiple Sclerosis (MS)

February 8, 2016 By Cade Hildreth (CEO) Leave a Comment

For patients with multiple sclerosis (MS), the Tisch MS Research Center of New York (MSRCNY) and its affiliated clinical practice, the International Multiple Sclerosis Management Practice, are important centers. They represent one of the few sites worldwide were clinical excellence is paired with cutting-edge research aimed at finding a cure for MS, a disease which affects 400,000 Americans and 2.5 million people worldwide.

In groundbreaking news released January 2016, the Tisch MS Research Center of New York (MSRCNY) announced that it is pursuing a Phase II clinical trial, exploring the use of spinal injections of neural progenitors derived from bone marrow mesenchymal stem cells (MSC-NPs) for the treatment of MS. [Read more…]

[*Note: Universal Cells was acquired by Japanese biopharmaceutical giant Astellas Pharma on February 14, 2018, for $102.5 million plus potential milestones.] [Read more…]

Interview with Dr. Racheli Ofir, VP of Research & IP at Pluristem Therapeutics

Cade Hildreth: What is your background and how did you get involved with Pluristem?

BioInformant's World-Class Clients

[Note: Universal Cells was acquired by Japanese biopharmaceutical giant Astellas Pharma on February 14, 2018, for $102.5 million plus potential milestones.]*
[Read more…]